CD8A and neoplasm: Interestingly, tumours with mesenchymal features seem to have elevated levels of PD-L1 and the highest presence of tumour-associated macrophages (TAMs), CD8+, CD3+ and FOXP3+T cells, which suggests they may be more immunoreactive by nature and therefore more sensitive to treatment with checkpoint inhibitors [9].